Astrazeneca (AZN) Invested Capital (2016 - 2025)

Astrazeneca has reported Invested Capital over the past 14 years, most recently at $78.3 billion for Q4 2025.

For Q4 2025, Invested Capital rose 10.08% year-over-year to $78.3 billion; the TTM value through Dec 2025 reached $78.3 billion, up 10.08%, while the annual FY2025 figure was $78.3 billion, 10.08% up from the prior year.
Invested Capital for Q4 2025 was $78.3 billion at Astrazeneca, up from $71.2 billion in the prior quarter.
Over five years, Invested Capital peaked at $78.3 billion in Q4 2025 and troughed at $66.3 billion in Q4 2022.
A 5-year average of $70.7 billion and a median of $70.1 billion in 2021 define the central range for Invested Capital.
Biggest five-year swings in Invested Capital: decreased 5.39% in 2022 and later grew 10.08% in 2025.
Year by year, Invested Capital stood at $70.1 billion in 2021, then fell by 5.39% to $66.3 billion in 2022, then grew by 2.26% to $67.8 billion in 2023, then increased by 4.98% to $71.2 billion in 2024, then grew by 10.08% to $78.3 billion in 2025.
Business Quant data shows Invested Capital for AZN at $78.3 billion in Q4 2025, $71.2 billion in Q4 2024, and $67.8 billion in Q4 2023.

Peer Comparison